Maria A Graziewicz

US Patent:

20070249538, Oct 25, 2007

Filed:

May 1, 2007

Appl. No.:

11/799117

Inventors:

Peter Sazani - Chapel Hill NC, US
Maria Graziewicz - Chapel Hill NC, US
Ryszard Kole - Chapel Hill NC, US

International Classification:

A61K 38/16
A61K 31/7052
A61P 29/00
C07H 21/00
C07K 14/00
C12N 1/00
C12N 15/00
C12N 15/63
C12N 5/00
C12P 21/00

US Classification:

514012000, 435243000, 435320100, 435325000, 435455000, 435069100, 514044000, 530350000, 536022100, 536023500

Abstract:

The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.

US Patent:

20120142759, Jun 7, 2012

Filed:

Oct 19, 2007

Appl. No.:

12/598453

Inventors:

Peter L. Sazani - Chapel Hill NC, US
Maria Graziewicz - Chapel Hill NC, US
Ryszard Kole - Chapel Hill NC, US

International Classification:

A61K 31/7088
A61P 29/00
C12N 5/02
C07H 21/04

US Classification:

514 44 R, 536 241, 435375

Abstract:

The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.